Summary:
Click image to enlargeThis study is a randomized, double-blind, placebo-controlled, dose-response study of BKR-017 and placebo that will be conducted at two investigative sites. The total duration of subject involvement is approximately 15 weeks; the screening period can be up to 3 weeks prior to the start of test period, followed by a 12-week test period. During the test period, subjects will self-administer three tablets of test product, two times daily: before breakfast and before bedtime.
Criteria:- Males and females between the ages of 18 and 70 years at the time of screening, inclusive
- Diagnosed with T2D and under the care of a healthcare professional for its management, or newly diagnosed (as participant in the study) with T2D
- HbA1c 6.5% -10.5%, inclusive
- Has given written informed consent to participate in this study
- Willing to complete 84-day test period
- Willing to maintain current diet and exercise routine and current prescription medications for the duration of the study
If you are interested in this study please fill out the contact form.
Qualified Participants May Receive:
Qualified participants will be compensated $250 for completion of the study. If a participant does not complete the entire study, he/she will receive $50 for each completed visit, except the Screening Visit (Visit 1) for which the participant will not receive compensation.